Clinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy: results from the CLEAR study

Nasloon  Ali; Stephanie  Chen; Trung N Tran; Bill Cook; Alan Altraja; Arnaud Bourdin; Chau-Chyun  Sheu; Ming-Ju  Tsai; Flavia C L  Hoyte; Anna Quinton; Benjamin  Emmanuel; Celine Y.Y. Goh; Victoria Carter; David Price

Clinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy: results from the CLEAR study

Nasloon Ali, Stephanie Chen, Trung N Tran, Bill Cook, Alan Altraja, Arnaud Bourdin, Chau-Chyun Sheu, Ming-Ju Tsai, Flavia C L Hoyte, Anna Quinton, Benjamin Emmanuel, Celine Y.Y. Goh, Victoria Carter, David Price

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Publication status	Accepted/In press - 5 Sep 2022
Event	CHEST Annual Meeting - Nashville, United States Duration: 16 Oct 2022 → 19 Oct 2022 https://www.chestnet.org/Learning-and-Events/Events/CHEST-Annual-Meeting

Conference

Conference	CHEST Annual Meeting
Country/Territory	United States
City	Nashville
Period	16/10/22 → 19/10/22
Internet address	https://www.chestnet.org/Learning-and-Events/Events/CHEST-Annual-Meeting

Cite this

Ali, N., Chen, S., Tran, T. N., Cook, B., Altraja, A., Bourdin, A., Sheu, C-C., Tsai, M-J., Hoyte, F. C. L., Quinton, A., Emmanuel, B., Goh, C. Y. Y., Carter, V., & Price, D. (Accepted/In press). Clinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy: results from the CLEAR study. Abstract from CHEST Annual Meeting, Nashville, Tennessee, United States.

Clinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy : results from the CLEAR study. / Ali, Nasloon ; Chen, Stephanie ; Tran, Trung N et al.

2022. Abstract from CHEST Annual Meeting, Nashville, Tennessee, United States.

Research output: Contribution to conference › Abstract › peer-review

Ali, N, Chen, S, Tran, TN, Cook, B, Altraja, A, Bourdin, A, Sheu, C-C, Tsai, M-J, Hoyte, FCL, Quinton, A, Emmanuel, B, Goh, CYY, Carter, V & Price, D 2022, 'Clinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy: results from the CLEAR study', CHEST Annual Meeting, Nashville, United States, 16/10/22 - 19/10/22.

@conference{056ea54fcba545b886109d7ceae894e8,

title = "Clinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy: results from the CLEAR study",

author = "Nasloon Ali and Stephanie Chen and Tran, {Trung N} and Bill Cook and Alan Altraja and Arnaud Bourdin and Chau-Chyun Sheu and Ming-Ju Tsai and Hoyte, {Flavia C L} and Anna Quinton and Benjamin Emmanuel and Goh, {Celine Y.Y.} and Victoria Carter and David Price",

note = "Funding This study was funded by AstraZeneca. The International Severe Asthma Registry is jointly funded by Optimum Patient Care Global and AstraZeneca. Acknowledgments Medical writing support was provided by Madeleine Wynn, MRes, of PharmaGenesis London, London, UK, with funding from AstraZeneca.; CHEST Annual Meeting ; Conference date: 16-10-2022 Through 19-10-2022",

year = "2022",

month = sep,

day = "5",

language = "English",

url = "https://www.chestnet.org/Learning-and-Events/Events/CHEST-Annual-Meeting",

}

TY - CONF

T1 - Clinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy

T2 - CHEST Annual Meeting

AU - Ali, Nasloon

AU - Chen, Stephanie

AU - Tran, Trung N

AU - Cook, Bill

AU - Altraja, Alan

AU - Bourdin, Arnaud

AU - Sheu, Chau-Chyun

AU - Tsai, Ming-Ju

AU - Hoyte, Flavia C L

AU - Quinton, Anna

AU - Emmanuel, Benjamin

AU - Goh, Celine Y.Y.

AU - Carter, Victoria

AU - Price, David

N1 - Funding This study was funded by AstraZeneca. The International Severe Asthma Registry is jointly funded by Optimum Patient Care Global and AstraZeneca. Acknowledgments Medical writing support was provided by Madeleine Wynn, MRes, of PharmaGenesis London, London, UK, with funding from AstraZeneca.

PY - 2022/9/5

Y1 - 2022/9/5

M3 - Abstract

Y2 - 16 October 2022 through 19 October 2022

ER -